Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track Of Review Designations: BTDs For X4, F2G, And BMS; Another QIDP For Allergan

Executive Summary

The latest news about products accepted into US FDA expedited review programs.

You may also be interested in...



Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Narrow HCC CheckMate-459 Miss For Opdivo Points The Way For Combos, Roche Shows How

Full data at ESMO show Opdivo managed to scrape a tolerability edge over standard-of-care sorafenib in liver cancer, but eyes were drawn to Roche’s early study of Tecentriq/Avastin as the way forward in this difficult-to-treat cancer.

AstraZeneca, Allergan Sign Another Antibiotic Pact

Allergan Inc. and AstraZeneca plc will join forces to further develop and commercialize ATM-AVI, a fixed-dose antibiotic for the treatment of infections caused by metallo β-lactamase (MBL)-producing Gram-negative pathogens – bacteria for which there are few viable antibiotics.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel